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Abstract 
On the basis of animal studies, the chemopreventive activity of isothiocyanates has 
been linked to their ability to modulate carcinogen-metabolising enzyme systems, 
including cytochromes P450. However, the potential of isothiocyanates to influence 
these enzyme systems in human liver has not been investigated. We have evaluated 
the modulation of cytochrome P450 expression in two human liver samples by erucin 
and sulforaphane, in comparison to rat, following the incubation of precision-cut 
human and rat liver slices with the two isothiocyanates. Both compounds failed to 
influence cytochrome P450 activity, as exemplified by the dealkylations of methoxy-, 
ethoxy- and pentoxyresorufin, and benzyloxyquinoline, in either human or rat liver. 
Impairment of activity was, however, observed in some activities at high 
concentrations (50 μM), which was attributed to toxicity. At the apoprotein level, 
however, both compounds elevated markedly CYP1A2/1B1 levels in rat liver, but in 
human liver only a modest increase was evident, and only in one of the livers. 
CYP3A2 apoprotein levels were modestly elevated in rat liver by both isothiocyanates 
both of which, however, failed to influence CYP3A4 expression in human liver. 
Neither isothiocyanate, in either rat or human liver, modulated CYP2B apoprotein 
levels. It may be inferred that (a) human and rat liver differ in their response to erucin 
and sulforaphane; (b) erucin and sulforaphane, despite being small molecular weight 
aliphatic compounds, up-regulate the CYP1 family but no increase in activity is 
observed as a result of mechanism-based inhibition, and (c) the chemopreventive 
effect of isothiocyanates, at dietary levels of intake, is unlikely to be due to inhibition 
of the cytochrome P450-mediated bioactivation of carcinogens. 
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Introduction  
Brassica vegetable consumption is increasingly being linked to low cancer incidence 
in epidemiological studies (Hecht, 2000; London et al., 2000; Ambrosone et al., 2004; 
Zhao et al., 2007; Higdon et al., 2007). Furthermore, isothiocyanates, which are 
encountered at substantial levels in these vegetables where they are present as 
glucosinolates, have also been linked to low cancer incidence (Lin et al., 1998; Spitz 
et al., 2000) and, in addition, they have been demonstrated repeatedly to afford 
protection against the carcinogenic effects of chemicals in laboratory studies in 
animal models (Hecht, 2000).  
One of the most extensively studied isothiocyanates is sulforaphane [1-
isothiocyanato-4-(methylsulphinyl) butane], its principal source being broccoli, where 
it is encountered as the glucosinolate, glucoraphanin. Sulforaphane has been shown 
repeatedly to afford protection against chemical carcinogens in animal models of 
cancer (Zhang et al., 2004; Chung et al., 2000; Fahey et al., 2002; Shen et al., 2007). 
Erucin [1-isothiocyanato-4-(methylthio)-butane] is a structurally related 
isothiocyanate to sulforaphane, its principal source being rocket salad, and is also a 
major metabolic product of sulforaphane, at least in rat (Kassahun et al., 1997; 
Bheemreddy and Jeffery, 2007). In a number of studies erucin has been shown to 
share similar biological activity with sulforaphane (Jakubíková et al., 2005; Barillari 
et al., 2005; Hanlon et al., 2008a and b). 
 Isothiocyanates appear to interfere beneficially in all stages of chemical 
carcinogenesis (Conaway et al., 2002; Zhang, 2004). As far as initiation is concerned, 
they act by limiting the production of genotoxic metabolites, which is achieved in two 
ways. Firstly, they are believed to impair the cytochrome P450-mediated bioactivation 
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of chemical carcinogens to their genotoxic intermediates and, secondly, they stimulate 
the detoxication of the genotoxic intermediates by up-regulating enzyme systems such 
as quinone reductase and glutathione S-transferases (Conaway et al., 2002; Zhang, 
2004). At dietary levels of intake, the latter mechanism appears to predominate 
(Yoxall et al., 2005; Konsue and Ioannides, 2008; Hanlon et al., 2008a).  
 Modulation of the cytochrome P450 enzyme systems by erucin and 
sulforaphane has been investigated largely in rodents (Conaway et al., 1996; Barcelo 
et al., 1996; Yoxall et al., 2005; Hanlon et al., 2008a), and the assumption is made 
that humans are likely to respond similarly to the same doses, thus providing a 
feasible mechanism to explain epidemiological findings.  Indeed, studies conducted in 
primary hepatocytes indicated the potential of sulforaphane to modulate cytochrome 
P450 expression in human liver (Maheo et al., 1997). 
The principal aim of our studies was to investigate whether sulforaphane and 
erucin influence cytochrome P450 activity and expression in similar manner in rat and 
human liver. Our studies focussed, in particular, on CYP1 as this family of 
cytochrome P450 enzymes is the most active in the bioactivation of chemical 
carcinogens, including polycyclic aromatic hydrocarbons, aflatoxin B1 and 
heterocyclic amines (Ioannides and Parke 1990; Ioannides and Lewis 2004).To attain 
this objective, studies were conducted in precision-cut slices from the liver of rats and 
two human donors. The principal advantages of this in vitro system are that it 
maintains tissue architecture and cell-cell communication, and it allows the facile 
comparison of animal species exposed to a wide range of concentrations of chemicals, 
that would otherwise necessitate large animal numbers for commensurate in vivo 
studies (Lerche-Langrand and Toutain, 2000). Studies emanating from our and other 
laboratories have established that precision-cut slices are an appropriate system for 
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use in evaluating the potential of xenobiotics to modulate cytochrome P450 activities 
in rodent and human liver (Lake et al 1993; Edwards et al 2003; Pushparajah et al 
2007, 2008).  
In this study we report for the first time modulation of cytochrome P450 
expression and activity in human liver by erucin and sulforaphane, in comparison to 
rat, following incubation, under identical conditions, of precision-cut human and rat 
liver slices with the two isothiocyanates. 
 
Materials and Methods 
Sulforaphane and erucin (LKT Laboratories, Minnesota, USA), NADPH, 
ethoxyresorufin, pentoxyresorufin, resorufin, peroxidase-linked anti-rabbit and anti-
goat antibodies (Sigma Co. Ltd., Poole, Dorset, UK), 7-benzyloxyquinoline and 7-
hydroxyquinoline (BD Biosciences, California USA) were all purchased. Rat anti-
CYP1A1, recognising both CYP1A1 and CYP1A2, anti-CYP1B1, anti-CYP2B and 
anti-CYP3A2, which also recognises human CYP3A4, antibodies were obtained from 
BD Biochemicals (Oxford, UK). 
 Male Wistar albino rats (about 180 g) were obtained from B&K Universal Ltd 
(Hull, East Yorkshire, UK). The animals were housed at 22 ± 2 °C, 30-40 % relative 
humidity, in an alternating 12-hr light:dark cycle with light onset at 07.00 hr. Liver 
sections from two human cadaveric livers that could not be used for transplantation 
purposes were obtained from the UK Human Tissue Bank (The Innovation Centre, 
Oxford Street, Leicester, U.K). Both donors died following lethal brain injury. Donor 
1 was a 26-year old male smoker who was maintained on ventilation for four days 
prior to death, whereas Donor 2 was a 54-year old non-smoking female who was 
maintained on artificial ventilation for two days prior to death ; both were Caucasian. 
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Liver sections were transported in cold University of Wisconsin (UW) preservation 
solution on ice. The time interval from the moment of donors’ death to the beginning 
of the incubation did not exceed 12h on both occasions.  On receipt, the liver sections 
were immediately transferred into a sterile container and, after the UW solution was 
carefully decanted, were washed 3 to 4 times with culture medium.  
Rat and human liver slices (250 m) were prepared from 8mm cylindrical 
cores using a Krumdieck tissue slicer (Alabama Research and Development 
Corporation, Munsford, AL, USA) as previously described (Hashemi et al., 1999). 
The multiwell plate procedure, using 12-well culture plates, was used to culture the 
slices. One slice was placed in each well, in 1.5 ml of culture medium. Slices were 
incubated under sterile conditions on a reciprocating plate shaker housed in a 
humidified incubator, at a temperature of 37 ºC and under an atmosphere of 95 % 
air/5% CO2. The slices were initially pre-incubated for 30 min in order to slough off 
any dead cells due to slicing. Three different slice pools, each comprising 10-12 rat or 
human slices, were used per time point.  
Following incubation, slices were removed from culture media, homogenised 
and post-mitochondrial supernatants prepared and stored at -80° C. When required, 
microsomes were isolated by centrifugation (105 000g x 1 hour). The dealkylations of 
methoxy- (Burke and Mayer, 1983) ethoxy- (Burke and Mayer, 1983), pentoxy-
resorufin (Lubet et al., 1985) and 7-benzyloxyquinoline (Stresser et al., 2002), and 
protein content (Bradford, 1976) were determined. Finally, in order to monitor 
changes in enzyme protein expression, hepatic microsomal proteins were resolved by 
electrophoresis and incubated with the primary antibody and the corresponding 
peroxidase-linked secondary antibody. Immunoblots were quantitated by 
densitometry using the GeneTool software (Syngene Corporation, Cambridge, UK).  
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Statistical evaluation was carried out employing Student’s t-test. 
Results  
Incubation of rat liver slices with erucin had no effect on the various cytochrome 
P450-mediated dealkylations, except in the case of ethoxy- and methoxyresorufin 
where impairment of activity was observed, but only at the highest concentration (50 
μM) (Figure 1). Similarly, no statistically significant change was noted when rat liver 
slices were incubated with sulforaphane, except at the highest concentration studied 
(50 μM) where the dealkylation of pentoxy- and methoxyresorufin were inhibited 
(Figure 2). However, both compounds markedly up-regulated CYP1A2 apoprotein 
levels, causing a trebling at an isothiocyanate concentration of 10 μM (Figure 3). Both 
compounds also up-regulated CYP1B1 apoprotein levels, but the effect was less 
pronounced compared with CYP1A2 (Figure 3). A modest rise in apoprotein levels 
was evident when rat microsomes were probed with anti-CYP3A2; neither compound 
elevated CYP2B apoprotein levels (Figure 3). 
 A similar picture emerged in cytochrome P450 activities when human liver 
slices were incubated under identical conditions with the two isothiocyanates. No 
change in any of the activities studied was observed in either of the human livers 
when slices were incubated with erucin, except for a decrease in activity at high 
concentrations (Figure 4). Similar observations were made when erucin was replaced 
with sulforaphane (Figure 5). Both compounds elevated modestly, in comparison to 
rat, CYP1A1 and CYP1B1 apoprotein levels in Donor 2, but not in Donor 1 (Figure 
6). Finally, neither compound modulated CYP2B or CYP3A4 apoprotein levels in 
either human liver, but a fall in levels was evident at the higher concentrations. 
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Discussion 
Experimental studies in animals led to the conclusion that a mechanism through 
which isothiocyanates may exert their chemopreventive activity is suppression of the 
cytochrome P450-mediated bioactivation of chemical carcinogens (Conaway et al., 
2002). To evaluate whether the same mechanism is operative in humans, studies were 
undertaken utilising precision-cut slices incubated with erucin and sulforaphane, two 
aliphatic isothiocyanates; similar studies were conducted in slices from rats, as the 
anticarcinogenic activity of this class of compounds has been established largely in 
this animal species. The study focussed on CYP1, undoubtedly the most active 
cytochrome P450 family in carcinogen bioactivation (Ioannides and Lewis, 2004; 
Ioannides and Parke, 1990), and the CYP2B subfamily, which is active in the 
bioactivation of nitrosamines (Shu and Hollenberg, 1997). Finally, as CYP3A4 is the 
dominant enzyme in the metabolism of drugs, the effect of erucin and sulforaphane on 
the hepatic levels of this enzyme was also monitored in order to assess whether 
interactions with drugs are likely to occur. Liver slices have been incubated with the 
isothiocyanates in question for 24 hours as previous studies have established that 
maximum induction is achieved at this time point (Pushparajah et al., 2007).  
In our previous studies, confined to hepatic phase II enzyme systems, we 
identified species differences when comparing the effects erucin and sulforaphane in 
human and rat liver (Hanlon et al., 2008b); consequently, current studies were 
conducted in both species. In rat, both compounds elevated the levels of both 
CYP1A2 and CYP1B1 markedly, in concentration-dependent manner. In contrast, 
there was no effect, at the same concentrations, on the dealkylations of ethoxy- and 
methoxy-resorufin activities which are catalysed by the CYP1 family (Namkung et 
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al., 1988), confirming the outcome of our previous in vivo studies (Hanlon et al., 
2008a; Yoxall et al., 2005). This lack of concordance is most likely due to the fact 
that both these compounds are effective mechanism-based inhibitors of cytochrome 
P450 activity (Yoxall et al., 2005; Hanlon et al., 2008a). A cytochrome P450-
mediated metabolite, believed to be an isocyanate (Lee, 1996; Goosen et al., 2001), 
interacts covalently with the enzyme rendering it catalytically incompetent. Both 
compounds failed to similarly up-regulate CYP2B either at the activity, as 
exemplified by the depentylation of pentoxyresorufin (Namkung et al., 1988), or at 
the apoprotein level, whereas in the case of CYP3A2 there was modest rise in 
apoprotein levels but no effect on the associated activity of benzyloxyquinoline 
dealkylation (Stresser et al., 2002). Clearly, the effects of erucin and sulforaphane on 
the rat hepatic cytochrome P450 system are isoform-specific. It is pertinent to point 
out that CYP1 up-regulation was not confined to the liver, but was also manifested 
when rat lung slices were exposed to the same concentrations of these isothiocyanates 
(unpublished observations). It is also relevant to emphasise that following oral 
administration of sulforaphane to rats, at the dietary dose of 0.5 mg/kg, the peak 
plasma concentrations achieved were <0.3 μM i.e. below the lowest concentration 
employed in the present study (Hanlon et al.,  2008c), and modulation of cytochrome 
P450 expression at this level is improbable.  
At the highest concentration studied, both compounds suppressed cytochrome 
P450 activity. We believe this is the result toxicity, which is associated with depletion 
of glutathione (Hanlon et al., 2008b), as a result of its utilisation in the metabolism of 
the isothiocyanate. At this concentration we have reported toxicity in rat liver slices as 
reflected by increased leakage of lactate dehydrogenase.  
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 The effects of erucin and sulforaphane on cytochrome P450 expression were 
clearly much less pronounced in human liver slices compared with the observations 
made in rat slices, incubated with the isothiocyanates under identical conditions. As in 
the rat, none of the enzymes studied was modulated by either isothiocyanate; the 
inhibition seen at higher concentrations is, once again, most likely the consequence of 
toxicity, as at this concentration glutathione is similarly depleted in human liver slices 
as in rat (Hanlon et al., 2008b). At the apoprotein level, however, both compounds 
failed to markedly up-regulate levels as observed in the rat. Neither isothiocyanate 
had any effect on CYP1A2 and CYP1B1 apoprotein levels in the liver from Donor 1, 
but in the case of Donor 2 both compounds elevated expression of these enzymes, but 
much less effectively compared with rat. These observations point to a possible 
species difference in the up-regulation of CYP1 by these isothiocyanates; however, 
more human samples need to be investigated for an unequivocal conclusion to be 
drawn. Moreover, the presence of a polymorphism in the up-regulation of CYP1 in 
humans can not be excluded; the Ah receptor, which controls the up-regulation of 
CYP1 expression (Denison and Nagy, 2003), is polymorphically expressed in 
humans, although the impact of these alleles on the induction of CYP1 proteins is not 
entirely clear (Harper et al., 2002; Koyano et al., 2005). 
 The up-regulation of the CYP1 family by erucin and sulforaphane was an 
unexpected and surprising observation, as these are small molecular weight aliphatic 
compounds, and thus atypical inducers of this cytochrome P450 family. Extensive 
studies have shown that the inducers of the CYP1 family are essentially aromatic 
planar compounds, characterised by a large area/depth2 ratio (Lewis et al., 1986; 
1987). The most avid ligand to this receptor is the toxin TCDD (2,3,7,8-
tetrachlorodibenzo-p-dioxin), and strong agonists are mostly large hydrophobic planar 
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aromatic compounds such as the polycyclic aromatic hydrocarbons (Cheung et al 
1993; Machala et al., 2001; Denison and Nagy, 2003; Pushparajah et al., 2007), 
although compounds comprising a single substituted aromatic ring, such as 
diaminotoluenes, can also serve as agonists (Cheung et al., 1996). Erucin and 
sulforaphane, both small molecular weight aliphatic compounds, are clearly strong 
inducers of CYP1 family expression despite the fact that structurally they are unlikely 
to be Ah receptor agonists. However, it should be borne in mind that up-regulation of 
the CYP1 family, independent of binding to the Ah receptor, has been reported 
(Ayalogu et al, 1995; Boyd et al, 1995; Lesca et al., 1995). 
 In conclusion, we have demonstrated that in rat liver the small molecular 
weight aliphatic isothiocyanates, erucin and sulforaphane, up-regulate the CYP1 
family but the enzyme is not catalytically competent presumably due to mechanism-
based inhibition. The induction potency of these isothiocyanates was similar, so that it 
is likely that the effect of sulforaphane in the rat may be partly mediated by erucin, its 
major metabolite, at least in the rat (Kassahun et al., 1997; Bheemreddy and Jeffery, 
2007). Similar studies in livers from two human donors showed, however, only a 
relatively modest rise in CYP1 expression in one of the livers with no effect on the 
other, alluding to a species difference. Finally, our observations allow us to infer that 
the chemopreventive effect of these isothiocyanates, at least at dietary levels of intake, 
is unlikely to be due to inhibition of cytochrome P450 carcinogen activation, but may 
involve primarily enhanced detoxification of reactive intermediates (Hanlon et al 
2008a, 2008b). 
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Legends to figures 
Figure 1: Effect of erucin on cytochromes P450 in precision-cut rat liver slices.  
 
 
Liver slices were incubated in modified RPMI 1640 culture medium containing erucin 
(0 to 50 µM) for 24 h. EROD (A), MROD (B), PROD (C) and 7-BQ (D) activities 
were determined in the microsomal fraction. Values represent the means ± SD of 3 
pools of slices, with each analysis performed in duplicate. * P<0.05, ** P<0.01 and 
*** P<0.001.     
  
Figure 2: Effect of sulforaphane on cytochromes P450 in precision-cut rat liver 
slices.  
 
Liver slices were incubated in modified RPMI 1640 culture medium containing 
sulforaphane (0 to 50 µM) for 24 h. EROD (A), MROD (B), PROD (C) and 7-BQ (D) 
activities were determined in the microsomal fraction. Values represent the means ± 
SD 3 pools of slices, with each analysis performed in duplicate. *P<0.05, ** P<0.01 
and *** P<0.001.     
 
Figure 3: Modulation by erucin (A) and sulforaphane (B) of cytochrome P450 
apoprotein levels in precision-cut liver slices.  
 
Liver slices were incubated in modified RPMI 1640 culture medium containing either 
erucin or sulforaphane (0 to 50 µM) for 24h. Hepatic microsomal proteins were 
resolved by 10 % (w/v) SDS-PAGE and then transferred electrophoretically to 
Hybond-P polyvinylidene difluoride membranes. Immunoblot analysis was carried 
out using rat antibodies to cytochrome P450 proteins, followed by the appropriate 
peroxidase-labelled secondary antibody. Each lane was loaded with 10 (CYP2B1 and 
CYP3A2) or 40 µg (CYP1A and CYP1B1) of total protein. Molecular markers were 
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run concurrently to aid band identification. The values in italics show percentage 
optical density relative to control.   
 
Figure 4: Effect of erucin on cytochromes P450 in precision-cut human liver 
slices  
 
Slices were generated from the livers of two donors and incubated in modified RPMI 
1640 culture medium containing erucin (0 to 50 µM) for 24 h. The activities of 
EROD, MROD and 7-BQ demethylase were determined in the microsomal fraction 
using ethoxyresorufin (A), methoxyresorufin (B) and 7-benzyloxyquinoline (C) as 
substrates. Values represent the means ± SD of 3 pools of slices, with each analysis 
performed in duplicate. * P<0.05, ** P<0.01 and *** P<0.001.     
 
Figure 5: Effect of sulforaphane on cytochromes P450 in precision-cut human 
liver slices  
 
Slices were generated from the livers of two donors and incubated in modified RPMI 
1640 culture medium containing sulforaphane (0 to 50 µM) for 24 h. The activities of 
EROD (A), MROD (B) and 7-BQ demethylase (C) were determined in the 
microsomal fraction. Values represent the means ± SD of 3 pools of slices, with each 
analysis performed in duplicate. * P<0.05, ** P<0.01 and *** P<0.001.     
 
Figure 6: Modulation of cytochrome P450 apoprotein levels by erucin and 
sulforaphane in human liver.  
 
Slices from two human livers were incubated in modified RPMI 1640 culture medium 
containing erucin or sulforaphane (0 to 50 µM) for 24 h. Hepatic microsomal proteins 
were resolved by 10 % (w/v) SDS-PAGE and then transferred electrophoretically to 
Hybond-P polyvinylidene difluoride membranes. Immunoblot analysis was carried 
out using rat antibodies to cytochrome P450 enzymes, followed by the appropriate 
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peroxidase-labelled secondary antibody. Each lane was loaded with 20 (CYP1A and 
CYP3A4) or 40 µg (CYP2B1 and CYP1B1) of total protein. Molecular markers were 
run concurrently to aid band identification. The values in italics show percentage 
optical density relative to control.   
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